drugset / Trial / NCT01128322

CKD-828 Primary Hypertension Trial(Dose-selection)

NCT01128322

Phase 2 Completed 430 enrolled Chong Kun Dang Pharmaceutical
RandomizedFactorialTriple-blindTreatment

Summary

The aim of this trial is to determine the best dose combination of S-Amlodipine and Telmisartan as compared to monotherapy by assessing the blood pressure lowering effects of a once daily regimen of various combinations of S-Amlodipine and Telmisartan, compared to their monotherapy components and placebo, in patients with stage I or II essential hypertension(a mean seated cuff diastolic blood pressure \>=95 and \<=115 mmHg).

Timeline

Start
2010-07
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator S-amlodipine Unknown 2.5 mg
Comparator S-amlodipine Unknown 5 mg
Comparator Telmisartan Other / unclassified 40 mg
Comparator Telmisartan Other / unclassified 80 mg